Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB/FLU-01L vaccine for pulmonary tuberculosis
NCT03017378Phase 1Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TB/FLU-01L in Tuberculosis (TB), sponsored by Research Institute for Biological Safety Problems. Primary endpoints: Adverse Events - Immediate reactions at 2 hours and Solicited local and systemic reactions at 7 days. Started Oct 2013; status: completed.
02
Drugs
TB/FLU-01L
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03017378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03017378.